On February 4—in Las Vegas, at the National Automobile Dealers Association (NADA) Show — FF will hold a final launch of its first EAI robotics products and begin sales. FX Super One will continue to expand its pre-order pipeline and extend its market coverage to ten key states, leading the First Class EAI-MPV era across the U.S. and the Middle East. FF will strive to achieve its 2026 market cap targets to maximize value for stockholders, with the goal to achieve dual growth in revenue and contribution margin, reach positive operating cash flow as early as possible, and move decisively toward a profitability inflection point. FF will further solidify its dual-public-company governance framework and continue building an AI-driven operating system for the company.LOS ANGELES, Jan. 11, 2026 (GLOBE NEWSWIRE) — Faraday Future Intelligent...

Richard Francis, Teva’s President and CEO, will present at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026, at 8:15 A.M. Pacific Time (11:15 A.M. Eastern Time) TEL AVIV, Israel, Jan. 11, 2026 (GLOBE NEWSWIRE) — Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) will present its ongoing transformation and expected growth trajectory through 2030 at the 44th Annual J.P. Morgan Healthcare Conference. Teva’s President and Chief Executive Officer, Richard Francis, will meet with investors and present the Company’s milestones achieved in 2025, transformative initiatives, and forward-looking outlook for 2026 and beyond. Presentation Highlights:Pivot to Growth Strategy Progress: Teva is accelerating its Pivot to Growth strategy, focusing on transforming into a leading innovative biopharmaceutical...

– Reports $156 to $160 Million in Preliminary* Full-Year 2025 U.S. Net Product Sales, a 35% to 38% Increase Compared With Full-Year 2024 – –Total Preliminary* Revenue of $400 to $408 million, a 20% to 23% Increase Compared With Full-Year 2024, and ~55% to 59% Increase Excluding One-Time Milestones – – Cash and Cash Equivalents of Approximately $168 Million* at Year-End 2025 – – Q4 Retail Prescription Equivalents Grew 34% Y/Y and 11.3% Q/Q –        – Expects Operating Expenses of Between $210 Million and $245 Million for Full-Year 2026 – – Introduces Vision 2040 Growth Strategy Focused on Global Growth of Cardiometabolic Franchise and Expansion of Pipeline into Rare Hepatic and Renal Diseases – ANN ARBOR, Mich., Jan. 11, 2026 (GLOBE NEWSWIRE) — Esperion (NASDAQ: ESPR) today provides preliminary financial results for the full-year...

Positive Phase 3 HERIZON-GEA-01 results for Ziihera® (zanidatamab-hrii) in first-line HER2-positive (HER2+) gastroesophageal adenocarcinoma (GEA) presented at ASCO GI Up to $440.0 million in milestone payments eligible to be earned related to regulatory approvals of Ziihera in GEA in the United States, Europe, Japan, and China Company well-positioned to execute new strategy compounding long-term value by integrating royalty growth, strategic acquisitions, and continued internal R&D innovation $125.0 million share repurchase plan announced in November 2025 available to reduce share count Cash, cash equivalents, and marketable securities of approximately $270.6 million (unaudited) as of December 31, 2025, combined with anticipated regulatory milestone payments related to potential approvals of Ziihera in GEA, expected to provide cash...

– Launched KOMZIFTI™ (ziftomenib), first and only once-daily, oral menin inhibitor approved for adults with R/R NPM1-mutated AML – – $2.1 million KOMZIFTI net product revenue for the period from first commercial sale on November 21, 2025, through December 31, 2025 – – Company poised for breakthrough progress in 2026 with deep pipeline of potentially transformative therapies – SAN DIEGO, Jan. 11, 2026 (GLOBE NEWSWIRE) — Kura Oncology, Inc. (Nasdaq: KURA), a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today highlighted recent accomplishments, reported preliminary KOMZIFTI™ (ziftomenib) net product revenue and outlined anticipated 2026 milestones. “Following the landmark FDA approval of KOMZIFTI on November 13, 2025, we are executing a robust commercial...

Royalty Pharma to provide up to $500 million, including $75 million for Phase 2b funding and a Royalty Pharma option for an additional $425 million to support Teva’s anti-IL-15 candidate TEV-‘408 TEV-‘408 is currently in Phase 1b for treatment of vitiligo and in Phase 2a for celiac disease Funding agreement supports Teva’s Pivot to Growth strategy to accelerate its innovative pipeline and bring treatments to patients fasterPARSIPPANY, N.J., and NEW YORK, Jan. 11, 2026 (GLOBE NEWSWIRE) — Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), and Royalty Pharma plc (Nasdaq: RPRX), today announced a funding agreement of up to $500 million to accelerate the clinical development of Teva’s anti-IL-15 antibody, TEV-’408. IL-15 is a key cytokine involved in multiple immune-mediated disease...

Preliminary 2025 net product revenue of $155.4 million, representing 172% year-over-year growth; OJEMDA 2026 U.S. net product revenue projected to be $225 – $250 million Company to present on corporate progress and priorities for 2026 during J.P. Morgan Healthcare Conference, January 12th at 5:15 pm PT (8:15 pm ET) BRISBANE, Calif., Jan. 11, 2026 (GLOBE NEWSWIRE) — Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN) (“Day One” or the “Company”), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced the release of preliminary unaudited 2025 OJEMDA™ net product revenue, cash and investments at year-end and provided 2026 OJEMDA net product revenue guidance ahead of the company’s scheduled presentation tomorrow at the...

Alignment Reached with U.S. FDA on Potential Accelerated Approval Pathway for BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) Based on Biomarker Endpoints U.S. Biologics Licensing Application (BLA) Submission for risto-cel (Previously Known as BEAM-101) Expected as Early as Year-End 2026 Expansion of Liver-targeted Genetic Disease Franchise Underway with New Program to be Announced in First Half of 2026   Ended 2025 with Estimated $1.25 Billion in Cash, Cash Equivalents and Marketable Securities; Projected Operating Runway Extension into 2029 Supports Anticipated risto-cel Launch and Execution of BEAM-302 Pivotal Development Plan CAMBRIDGE, Mass., Jan. 11, 2026 (GLOBE NEWSWIRE) — Beam Therapeutics Inc. (Nasdaq: BEAM) today announced continued progress toward its mission to build a sustainable, predictable model for the advancement...

Royalty Pharma to provide up to $500 million, including $75 million for Phase 2b funding and a Royalty Pharma option for an additional $425 million, to support Teva’s anti-IL-15 candidate, TEV-‘408  TEV-‘408 is currently in Phase 1b for treatment of vitiligo and in Phase 2a for celiac disease Funding agreement supports Teva’s Pivot to Growth strategy to accelerate its innovative pipeline and bring treatments to patients fasterNEW YORK and PARSIPPANY, N.J., Jan. 11, 2026 (GLOBE NEWSWIRE) — Royalty Pharma plc (Nasdaq: RPRX) and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced a funding agreement of up to $500 million to accelerate the clinical development of Teva’s anti-IL-15 antibody, TEV-‘408. IL-15 is a key cytokine involved in multiple immune-mediated...

2025 total revenue expected to exceed $340 million, above the previously guided range of $327-335 million 2025 total test reports for our core revenue drivers (DecisionDx®-Melanoma, TissueCypher®) increased 37% over 2024 Year-end 2025 cash, cash equivalents and marketable investment securities expected to be approximately $300 million FRIENDSWOOD, Texas, Jan. 11, 2026 (GLOBE NEWSWIRE) — Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced certain unaudited preliminary performance results for the fourth quarter and year ended Dec. 31, 2025. “We are extremely pleased with our excellent fourth quarter and full year preliminary results, which reflect both the strength of our innovative test portfolio and the dedication of the entire Castle team,” said...